Want to see SE:NXTCL full AI Analyst Report?

NextCell Pharma AB (NXTCL) Price & Analysis

1 Followers

NXTCL Stock Chart & Stats

kr0.92

kr0.02(0.56%)

At close: Mar 06 4:00 PM EST

kr0.92

kr0.02(0.56%)

Day’s Range― - ―

52-Week Rangekr0.63 - kr1.78

Previous CloseN/A

Volume77.06K

Average Volume (3M)398.49K

Market Cap

kr133.72M

Enterprise Valuekr97.59

Total Cash (Recent Filing)kr21.09M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.63

Next Earnings

Oct 22, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.38

Shares Outstanding126,392,960

10 Day Avg. Volume480,160

30 Day Avg. Volume398,494

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)1.7

Revenue Forecast (FY)kr254.00M

Bulls Say, Bears Say

Bulls Say

Proprietary Cell-therapy PlatformA proprietary stem-cell platform and related cell-banking capabilities give NextCell an integrated foundation across therapeutic development and potential commercialization. If successfully validated, this model could support repeatable applications, strengthen differentiation, and create longer-term strategic value beyond a single program.

Debt-free Balance SheetThe absence of reported debt reduces refinancing pressure and interest obligations, giving the company greater flexibility than a similarly loss-making biotech with leverage. This balance-sheet feature can help preserve strategic options while clinical and commercialization activities continue to develop.

Historical Revenue GrowthRevenue growth over the trailing period and preceding annual periods indicates that the business has generated some commercial expansion despite remaining unprofitable. Continued adoption of its products and services could provide a base for future operating leverage if margins improve as development activities mature.

Bears Say

Deeply Negative Gross MarginsGross losses of this scale relative to revenue show that the current business model is not yet covering direct operating costs. Without a substantial improvement in product economics, pricing, or mix, revenue growth may continue to require external funding rather than translate into durable profitability.

Persistent Cash BurnSustained negative operating and free cash flow indicates that ongoing activities consume significant capital and have not reached self-funding status. This weakens financial durability, increases reliance on future financing or other capital sources, and can constrain investment in clinical and commercial execution.

Eroding Equity BaseThe substantial reduction in equity reflects the cumulative effect of persistent losses and cash consumption, leaving a smaller capital base to support future development. Continued erosion could reduce resilience, limit strategic flexibility, and make additional funding increasingly important to sustain operations.

NXTCL FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was kr0.63 and its highest was kr1.78 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is kr133.72M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is Oct 22, 2026 which is in 36 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on Aug 27, 2026. The company reported -kr0.092 earnings per share for the quarter.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 126,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -kr0.092 in its last earnings report. Following the earnings report the stock price went down -1.318%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in SE:NXTCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.